CELL INTELLIGENCE · 肿瘤细胞治疗研究

富马酸二甲酯通过激活 mtDNA-cGAS-STING 通路重编程宫颈癌细胞以增强抗肿瘤免疫

Dimethyl fumarate reprograms cervical cancer cells to enhance antitumor immunity by activating mtDNA-cGAS-STING pathway.

该研究阐明，DMF 重编程 CC 细胞以激活 mtDNA-cGAS-STING 通路，进而形成富含趋化因子的微环境，招募 CD8⁺ T 细胞。

宫颈癌转移淋巴结来源的 TIL（肿瘤浸润淋巴细胞）的 T 细胞受体库特征及治疗潜力

T cell receptor repertoire characteristics and therapeutic potential of tumor infiltrating lymphocytes (TILs) derived from metastatic lymph node in ce

探索罕见肿瘤的个体化用药机会与优化 TIL（肿瘤浸润淋巴细胞）治疗：一项基于类器官的神经内分泌肿瘤患者全流程临床映射研究

Discover personalized drug opportunity and optimized tumor-infiltrating lymphocyte therapy for rare cancer: an organoid-based whole-journey clinical m

本研究证实，罕见癌症患者的生存取决于整合的、个体化的伴随诊断与治疗优化。

多组学分析揭示γδ T 淋巴细胞在改善宫颈癌肿瘤微环境、免疫治疗疗效及预后方面的益处

Multiomics profiling reveals the benefits of gamma-delta (γδ) T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and progn

γδ T 细胞在宫颈癌的抗肿瘤免疫中发挥有益作用。宫颈癌组织中γδ T 细胞的丰度与免疫治疗更高的缓解率相关。

宫颈癌的细胞免疫治疗：下一代治疗前沿

Cellular Immunotherapy for Cervical Cancer: Next Therapeutics Frontiers.

局部晚期宫颈癌辅助性自体 TIL（肿瘤浸润淋巴细胞）免疫治疗的 I 期研究

Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer.

自体 TIL（肿瘤浸润淋巴细胞）联合改良淋巴细胞清除方案清除复发宫颈癌患者的肿瘤

Eradicating tumor in a recurrent cervical cancer patient with autologous tumor-infiltrating lymphocytes and a modified lymphodepleting regimen.

宫颈癌 TIL（肿瘤浸润淋巴细胞）治疗的研究进展

Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer.

无 IL-2 的 TIL（肿瘤浸润淋巴细胞）治疗联合 PD-1 阻断在晚期妇科肿瘤中展现强效疗效

IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer.

我们改良的 TIL 治疗方案显示出可控的安全性，且 TIL 在不经静脉给予 IL-2 的情况下仍可存活并增殖，在晚期妇科肿瘤患者中显示出强效疗效。

过继性 TIL（肿瘤浸润淋巴细胞）治疗宫颈癌的研究进展

Research progress of adoptive tumor infiltrating lymphocyte therapy for cervical cancer.